Published in Oncol Rep on November 01, 2009
Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell (2014) 3.04
Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88
Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasion. Cancer Cell Int (2010) 1.01
L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer (2011) 0.98
Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Exp Ther Med (2014) 0.89
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol (2016) 0.86
Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells. J Cancer Res Clin Oncol (2012) 0.85
L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. BMC Cancer (2014) 0.84
L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer (2016) 0.81
Full-length L1CAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression. PLoS One (2011) 0.79
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget (2017) 0.78
L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PLoS One (2016) 0.77
Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. Oncotarget (2016) 0.76
Prognostic significance of L1 cell adhesion molecule in cancer patients: A systematic review and meta-analysis. Oncotarget (2016) 0.75
Orchestration of the crosstalk between astrocytes and cancer cells affects the treatment and prognosis of lung cancer sufferers with brain metastasis. J Thorac Dis (2016) 0.75
Mint3-mediated L1CAM expression in fibroblasts promotes cancer cell proliferation via integrin α5β1 and tumour growth. Oncogenesis (2017) 0.75
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Exosomes: from biogenesis and secretion to biological function. Immunol Lett (2006) 3.82
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res (2007) 2.62
L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol (2005) 2.39
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med (2011) 2.10
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res (2003) 2.04
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02
A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J (2006) 1.92
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett (2009) 1.84
Myeloperoxidase attracts neutrophils by physical forces. Blood (2010) 1.84
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82
Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer (2011) 1.76
Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res (2006) 1.75
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol (2002) 1.75
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 1.68
L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet (2003) 1.67
Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. J Clin Oncol (2010) 1.65
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol (2009) 1.65
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol (2013) 1.62
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J (2002) 1.58
CEACAM1+ myeloid cells control angiogenesis in inflammation. Blood (2009) 1.57
Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res (2005) 1.54
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat (2011) 1.53
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53
L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr (2012) 1.52
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res (2005) 1.50
High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica (2008) 1.47
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis (2015) 1.47
L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol (2005) 1.47
Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci Lett (2007) 1.41
Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res (2008) 1.41
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Tetrastarch sustains pulmonary microvascular perfusion and gas exchange during systemic inflammation. Crit Care Med (2012) 1.40
Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer (2002) 1.38
Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol (2011) 1.37
Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res (2006) 1.35
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol (2006) 1.33
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol (2009) 1.31
Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res (2012) 1.30
CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci (2006) 1.30
Cartilage destruction in granulomatosis with polyangiitis (Wegener's granulomatosis) is mediated by human fibroblasts after transplantation into immunodeficient mice. Am J Pathol (2012) 1.29
Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem (2007) 1.28
PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem (2011) 1.28
Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem (2008) 1.27
Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer (2011) 1.27
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med (2005) 1.27
L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol (2006) 1.25
Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res (2007) 1.24
Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem (2013) 1.22
Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol (2011) 1.22
CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol (2002) 1.21
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21
Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res (2009) 1.20
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci (2010) 1.20
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. Carcinogenesis (2012) 1.20
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Brain development in mice lacking L1-L1 homophilic adhesion. J Cell Biol (2004) 1.19
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol (2008) 1.19
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Inhibition of hyaluronan export from human fibroblasts by inhibitors of multidrug resistance transporters. Biochem Pharmacol (2004) 1.17
Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest (2004) 1.16
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat (2012) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res (2013) 1.15
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst (2004) 1.15
Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Cancer Res Treat (2007) 1.15
Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest (2010) 1.14
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14